Company Directory

Microbiome modulator ingredients for metabolic health and disease prevention

OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and gut microbiome diversity. Products are licensed to food and supplement manufacturers globally. The company operates through subsidiaries including OptiBiotix Ltd and holds a majority stake in SkinBioTherapeutics plc and ProBiotix Health Ltd.

Multiplex qPCR and NGS kits for molecular detection

YouSeq is a UK manufacturer of multiplex Next Generation Sequencing and qPCR kits, panels and reagents. The company offers one of the largest menus of qPCR targets available, covering human infectious diseases, antimicrobial resistance profiling, food and water safety, microbiome analysis, and veterinary diagnostics. Products are supplied as complete, ready-to-use kits compatible with standard laboratory platforms, serving clinical, research, and diagnostic laboratory customers.

Clinical-stage therapeutics for advanced liver disease

Yaqrit is a clinical-stage biotechnology company developing treatments for patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure. Its pipeline includes an oral ammonia scavenger for hepatic encephalopathy, an extracorporeal liver support device, and a microbiome-based therapeutic. Multiple programmes are in Phase 2–3 development. The company's science originates from over two decades of research by Professor Rajiv Jalan and his team at University College London and the Royal Free Hospital.

Contract research and analytical services for food and health industries

QIB Extra is a wholly owned commercial subsidiary of Quadram Institute Bioscience, providing contract research, analytical services, and consultancy to companies in the food, nutrition, and health sectors. Operating from Norwich Research Park, it gives commercial clients access to the facilities and scientific expertise of the Quadram Institute on a fee-for-service basis. Services include applied microbiology, food safety testing, bioactive analysis, gut health research, and sequencing. Clients range from SMEs to large multinationals.

Engineered bacteria to remodel the tumour microenvironment

Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable immune cell infiltration. The platform engineers tumour-colonising bacteria to break down stromal barriers that exclude immune cells, aiming to increase response rates to existing immunotherapies in patients with immune-cold tumours. Lead programmes target colorectal and pancreatic cancers, with first-in-human trials planned for 2027.

AI-powered microbiome and phage therapy platform for gut disorders

GutSee Health is a biotechnology company developing precision microbiome therapies for gut disorders including irritable bowel syndrome and inflammatory bowel disease. Its AI discovery platform integrates multi-omics and microbiome data to identify molecular disease signatures and therapeutic targets. A parallel programme uses machine learning to design targeted bacteriophage interventions that selectively remove harmful gut microbes and address antimicrobial-resistant wound infections.

Microbiome platform optimising hydroponic crop performance

Concert Bio is an agricultural biotechnology company developing microbial products to optimise crop performance in hydroponic greenhouses. Its platform combines the world's largest hydroponic microbiome database with machine learning to identify beneficial microbes tailored for soilless growing systems. The company's first commercial product has demonstrated average yield improvements of 9.9% across multiple crops in commercial grower trials. Concert Bio serves greenhouse growers across the UK and Europe.

Clinical skin microbiome testing and multi-omic ingredient analysis platform

Sequential Skin is a biotechnology company providing non-invasive clinical microbiome testing and multi-omic analysis services to the personal care and pharmaceutical industries. Using patch-based sampling and next-generation sequencing, the company quantifies how ingredients and formulations affect the skin microbiome and host biomarkers. Its proprietary dataset of over 50,000 samples and 4,000 ingredients underpins an AI-powered discovery engine for identifying and optimising next-generation bioactive compounds.

Contract microbial whole genome sequencing and metagenomics service

MicrobesNG Ltd is a UK-based contract sequencing service provider specialising in microbial whole genome and metagenome sequencing. The company processes bacterial, fungal, and viral samples using Illumina short-read and Oxford Nanopore long-read platforms, with DNA extraction and bioinformatics analysis included as standard. Services are accessible to academic, public sector, and commercial customers across more than 40 countries.

Canine gut microbiome testing and personalised supplement service

BIOME9 is a canine health company providing at-home gut microbiome testing and personalised supplement plans for dogs. Using stool sample analysis and AI-assisted interpretation, the company generates detailed gut health reports identifying microbial imbalances and tailored dietary recommendations. Operating as the scientific and laboratory partner to Pooch & Mutt, BIOME9 also works directly with veterinary clinics, behaviourists, and nutritionists to support canine gut health across clinical and consumer settings.

AI-powered gut microbiome analysis for personalised clinical nutrition

Enbiosis is a biotechnology company combining whole-genome gut microbiome sequencing with artificial intelligence to generate personalised nutrition, dietary, and supplement recommendations for patients with gastrointestinal disorders. Its B2B platform is used by healthcare professionals including gastroenterologists and dietitians to guide microbiome-targeted interventions, with a primary focus on irritable bowel syndrome and chronic constipation. The company also develops AI-designed nutraceutical formulations for supplement manufacturers. Clinical outcomes are supported by publications in peer-reviewed gastroenterology journals.

Food and gut health bioscience research on Norwich Research Park

Quadram Institute Bioscience is a BBSRC-funded independent research organisation focused on the interactions between food, gut microbiota, and human health. Operating within the Quadram Institute, a partnership with the University of East Anglia, Norfolk and Norwich University Hospitals, and BBSRC, it conducts fundamental and translational research across food safety, the gut microbiome, infectious disease, and healthy ageing. The institute also operates a clinical research facility and hosts one of Europe's largest gastrointestinal endoscopy centres.